BioNTech SE Files 6-K Amid NIH Discussions
Ticker: BNTX · Form: 6-K · Filed: Mar 25, 2024 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, collaboration-discussion
Related Tickers: BNTX
TL;DR
BioNTech's talking to the NIH, filing a routine 6-K. No big news yet.
AI Summary
BioNTech SE filed a Form 6-K on March 25, 2024, reporting on its ongoing discussions with the National Institutes of Health (NIH). The filing is a routine report for foreign private issuers and does not contain specific financial figures or new material events beyond the mention of these discussions.
Why It Matters
This filing indicates ongoing engagement between BioNTech and a significant governmental health organization, which could signal future collaborations or research initiatives.
Risk Assessment
Risk Level: low — The filing is a standard disclosure and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- BioNTech SE (company) — Registrant
- National Institutes of Health (company) — Party in discussions
- 001-39081 (other) — SEC File Number
- 20240325 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing by BioNTech SE?
The Form 6-K is a report of a foreign private issuer filed to provide information that the company has made or will make public in accordance with the laws of its home country or listing requirements.
What specific information is disclosed in this 6-K filing?
This filing primarily notes that BioNTech SE was in discussions with the National Institutes of Health (NIH) and is a routine report for the month of March 2024.
When was this Form 6-K filed with the SEC?
The filing was made on March 25, 2024.
Does this filing contain any financial results or material new events?
No, this specific filing does not appear to contain new financial results or material new events beyond the mention of ongoing discussions with the NIH.
What is BioNTech SE's principal executive office address?
BioNTech SE's principal executive offices are located at An der Goldgrube 12, D-55131 Mainz, Germany.
Filing Stats: 288 words · 1 min read · ~1 pages · Grade level 16.5 · Accepted 2024-03-22 17:33:34
Filing Documents
- form6-knihnotice22mar2024.htm (6-K) — 11KB
- 0001776985-24-000030.txt ( ) — 12KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF MARCH 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K BioNTech SE (the "Company") previously disclosed that the Company was in discussions with the National Institutes of Health ("NIH") concerning royalties and other amounts allegedly owed on sales of the Company's COVID-19 vaccine since commercialization, and that the NIH had delivered a communication threatening to send a notice of default under its license agreement with the Company. On March 22, 2024, the Company received a notice of default from the NIH relating to alleged amounts owed and breaches under such license. As previously disclosed, the Company disagrees with the positions being taken by the NIH, and intends to vigorously defend against all allegations of breach. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Dr. Sierk Poetting Name Dr. Sierk Poetting Title Chief Operating Officer Date March 22, 2024